Davy Research

UDG Healthcare plc

UDG Healthcare plc - Acquires Cambridge BioMarketing for up to $35m
Pharma and healthcare
UDG Healthcare plc

DAVY VIEW

The acquisition of Cambridge BioMarketing is UDG’s fifth acquisition this financial year, bringing total capital deployment on M&A to over $200m in FY2018. Similar to the $32m Vynamic deal last week, today’s $35m transaction is in-line with UDG’s strategy of growing Ashfield’s presence in both the communications/advisory space and the US market. It also reinforces UDG’s ability to transact at attractive multiples (estimated 7.5x EBIT). We estimate that the deal is c.2.5% accretive to earnings on a pro-forma basis.

Download full report with analyst certification and important disclosures
Download
Download full report with analyst certification and important disclosures
Download
  • RATINGS AND PRICE CORRECT AT TIME OF ISSUE


  • UDG Healthcare plc

    Closing Price: 1098p

  • RATING 12/06/17

  • PREVIOUS RATING N/A

Analyst(S)

COMPANY DATA

JUMP TO